Periostin-guided Withdrawal of Inhaled Corticosteroids in Non-eosinophilic Asthma
Asthma
Enrolment: 20 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Asthma
Enrolment: 20 · Results not recorded
Asthma
Enrolment: 54 · Results not recorded
Sinusitis · Nasal Polyps
Enrolment: 0 · Results not recorded
Severe Asthma
Enrolment: 16 · Results not recorded
Periodontitis · Smoking
Enrolment: 44 · Results not recorded
Periodontitis
Enrolment: 14 · Results not recorded
Coronary Artery Disease · Systemic Inflammatory Response · Chronic Coronary Syndrome · Atherosclerosis
Enrolment: 100 · Results not recorded
Severe Hemophilia A · Osteoporosis
Enrolment: 10 · Results not recorded
Chronic Periodontitis · Cardiovascular Diseases · Periodontal Inflammation
Enrolment: 45 · Results not recorded
Osteoporosis
Enrolment: 66 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Isoproterenol-induced myocardial injury, isoproterenol 85 mg/kg/day intraperitoneally
Periostin reduced the levels of the analysed markers, most notably cardiac troponins and creatine kinases, on days 7 and 28 after induced heart damage, which the authors interpret as a potential to increase the rate of myocardial recovery.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.